BCX vs BHRB

The company exhibits extremely weak financial health with a Piotroski F-Score of just 1/9, indicating significant fundamental deterioration. Despite a high dividend yield of 6.72%, the payout ratio of 141.63% is unsustainable, raising concerns about future cuts. Profitability metrics are entirely absent (0.00% margins), and most valuation and financial health data are unavailable, suggesting opacity or structural issues. While the stock has delivered strong price performance over the past year (+46.8%), it trades at a high P/E of 23.04 without corresponding growth or profitability, and lacks any Altman Z-Score to assess solvency risk.

BHRB presents a stark contrast between deep value and deteriorating fundamental health. While the stock trades significantly below its Graham Number ($98.78) and Intrinsic Value ($227.74) with a low P/E of 8.35, the Piotroski F-Score of 3/9 indicates weak financial health. Strong earnings growth (51.8% YoY) and a consistent track record of beating estimates are offset by a bearish technical trend and a lack of dividend support. The valuation is highly attractive, but the low health score necessitates a cautious approach.